A Single Center, Two-part, Double-blind, Randomized, Placebo-controlled, Dose-escalation, Phase 1 Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of BB-025 or Placebo, Alone and Following a Single Dose of BB-031, in Healthy Volunteers
Latest Information Update: 08 Oct 2025
At a glance
- Drugs BB 025 (Primary) ; BB 031 (Primary)
- Indications Blood coagulation disorders; Ischaemic stroke; Pulmonary embolism
- Focus Adverse reactions
- Sponsors Basking Biosciences
Most Recent Events
- 08 Oct 2025 New trial record